APPENDIX B

Clean copy of all claims currently under examination upon entry of the present amendment.

13. (Currently Amended) A method for treating diabetes in a mammal, said method comprising administering to said mammal a therapeutically-effective amount of an LXR agonist.

14. (Canceled)

16. (Reiterated) The method of Claim 13 further comprising administering to said mammal an additional active agent selected from the group consisting of an antihyperlipidemic agent; a plasma HDL-raising agent; antihypercholesterolemic agent; a cholesterol biosynthesis inhibitor; an acyl-coenzyme A: a cholesterol acyltransferase inhibitor; probucol; nicotinic acid and the salts thereof; niacinamide; a cholesterol absorption inhibitor; a bile acid sequestrant anion exchange resin; a low density lipoprotein receptor inducer; clofibrate, fenofibrate, gemfibrizol; vitamin B_6 and the pharmaceutically acceptable salts thereof; vitamin B_{12}; an anti-oxidant vitamin; a beta-blocker; an angiotensin II antagonist; an angiotensin converting enzyme inhibitor; a platelet aggregation inhibitor; a platelet aggregation inhibitor; a fibrinogen receptor antagonist; aspirin; a sulfonylurea; a biguanide, a thiazolidinedione; an insulin sensitizer; a dehydroepiandrosterone; an antiglucocorticoid; a TNFα inhibitor; an α-glucosidase inhibitor; pramlintide; an insulin secretogogue; insulin; phenylpropanolamine, phentermine, diethylpropion, mazindol; fenfluramine; dexfenfluramine; phentiramine; a β_3 adrenoceptor agonist agent; sibutramine; a gastrointestinal lipase inhibitor; a leptin; neuropeptide Y; enterostatin; cholecytokinin; bombesin; amylin; a histamine H_3 receptor; a dopamine D_2 receptor; melanocyte stimulating hormone; corticotrophin releasing factor; galanin; and gamma amino butyric acid (GABA).

17. (Currently amended). A method of preventing the onset of, reducing the risk of developing, or the risk of recurrence of, diabetes, said method comprising administering to said mammal a therapeutically-effective amount of an LXR agonist.

18. (Canceled)

21. (Reiterated) A method for treating type II diabetes in a mammal, said method comprising administering to said mammal a therapeutically-effective amount of an LXR agonist.

22. (Reiterated) A method for treating type II diabetes in a mammal and reducing the cardiovascular complications of type II diabetes, said method comprising administering to said mammal a therapeutically-effective amount of an LXR agonist.

23. (Reiterated) The method of claim 22 further comprising administering an additional active agent selected from the group consisting of a sulfonylureas; a biguanides, a thiazolidinedione; an insulin sensitizer; a dehydroepiandrosterone; an antiglucocorticoids; a TNFα inhibitor; an α-glucosidase inhibitor; pramlintide; an insulin secretogogues; and insulin.

25. (Canceled)

29. (New) The method of claim 13, wherein said treatment decreases hyperglycemia.

30. (New) The method of claim 13, wherein said treatment decreases insulin resistance.

31. (New) The method of claim 17, wherein said treatment decreases plasma glucose levels.

32. (New) The method of claim 17, wherein said method decreases insulin resistance.

33. (New) The method of claim 21, wherein said method decreases hyperglycemia.

34. (New) The method of claim 21, wherein said treatment decreases insulin resistance.

35. (New) The method of claim 22, wherein said treatment decreases insulin resistance.

36. (New) The method of claim 22, wherein said treatment decreases hyperglycemia.